Chronic Fatigue Syndrome Research Program
There currently exists no FDA approved treatment for Chronic Fatigue Syndrome (CFS). K-PAX Pharmaceuticals is currently developing what we hope will become the first by-prescription treatment for this condition. A multi-center double-blind, placebo-controlled trial is currently projected to begin enrolling patients in September 2013. Check here for more information or call 1-855-318-4673.
HIV/AIDS Research Program
For more information on the ongoing Canadian HIV/AIDS Study (The MAINTAIN Study) using K-PAX IMMUNE for people with early HIV infection, which is currently enrolling patients, please click here.
K-PAX Immune Support Formula was the micronutrient formula tested in a double-blinded, placebo-controlled clinical trial which demonstrated a positive effect on the immune systems of HIV(+) individuals on antiviral therapy.
HIV-infected patients taking a stable antiviral medication regimen were
randomized to either the K-PAX formula or placebo groups. After 12
weeks, the patients taking the K-PAX formula experienced an average 24%
increase in their CD4 count compared to no change in the placebo group
The mean absolute CD4 count also rose significantly by an average of 65 cells after 12 weeks in the micronutrient group versus a 6 cell decline in the placebo group (P=0.029).
This research study was presented at the 2006 World AIDS Conference in Toronto (Abstract #0402). It was also published in the August 2006 issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS) - Kaiser JD, et al. JAIDS 2006;42(5):523-528.
To download a copy of this study directly from the Journal of AIDS website click here
K-PAX IMMUNE and ENERGY are dietary supplements and are not indicated for the diagnosis, prevention, or treatment of any medical condition. Individual results may vary.